A new public offering of 4.5 million shares of common stock at $9.50 per share will help to float Regulus Therapeutics Inc.'s pipeline of drugs targeting microRNAs, including its lead compound RG-101 for hepatitis C virus. The offering is expected to raise gross proceeds of $42.8 million, and will close on or about July 22.